Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

8 Nov 2017

Abstract excerpt

Abstract Small cell lung cancer (SCLC) is a difficult to treat subtype of lung cancer. One of the hallmarks of SCLC is its almost uniform chemotherapy sensitivity. However, chemotherapy response is typically transient and patients frequently succumb to SCLC within a year following diagnosis. We performed a transcriptome analysis of the major human lung cancer entities. We show a significant overexpression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29138515
DOI: 10.1038/s41598-017-15840-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerPMID 29138515Read ↗

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with CisplatinSemantic proximity Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

Small cell lung cancer: Novel treatments beyond immunotherapySemantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Semantic proximity Read ↗

Treatment with the Chk1 inhibitor Gï¿½6976 enhances cisplatin cytotoxicity in SCLC cellsSemantic proximity Read ↗

Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.Semantic proximity Read ↗

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity Read ↗

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity Read ↗

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancerSemantic proximity Read ↗

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.